Verona Pharma Reports Operational Update and Financial Results for Full Year Ended December 31, 2017

Verona Pharma (Nasdaq:VRNA) a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces its audited results for the full year ended December 31, 2017.

As quoted in the press release:

Initiated four clinical studies, two of which have been successfully completed ahead of schedule:
• Reported in September 2017 positive top-line data from a Phase 2a clinical trial in COPD with RPL554 when dosed in addition to tiotropium (Spiriva®), compared to placebo:
• Demonstrated statistical significance across all primary and secondary efficacy outcome measures, as well as a clear dose response;
• Achieved significant and clinically meaningful additional improvement in peak lung function when added to tiotropium, a widely used drug to treat COPD;

Click here to read the full press release.